Stratos Wealth Partners LTD. Sells 613 Shares of Sanofi (NASDAQ:SNY)

Stratos Wealth Partners LTD. cut its stake in Sanofi (NASDAQ:SNY) by 10.8% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 5,057 shares of the company’s stock after selling 613 shares during the period. Stratos Wealth Partners LTD.’s holdings in Sanofi were worth $244,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. AQR Capital Management LLC bought a new stake in shares of Sanofi during the second quarter valued at approximately $344,000. Creative Planning lifted its position in Sanofi by 18.0% during the third quarter. Creative Planning now owns 220,763 shares of the company’s stock valued at $12,723,000 after buying an additional 33,728 shares during the period. Asset Dedication LLC boosted its holdings in shares of Sanofi by 284.1% during the 3rd quarter. Asset Dedication LLC now owns 3,902 shares of the company’s stock valued at $225,000 after buying an additional 2,886 shares in the last quarter. Probity Advisors Inc. grew its position in shares of Sanofi by 4.9% in the 3rd quarter. Probity Advisors Inc. now owns 14,413 shares of the company’s stock worth $831,000 after buying an additional 671 shares during the period. Finally, Mezzasalma Advisors LLC grew its position in shares of Sanofi by 3.0% in the 3rd quarter. Mezzasalma Advisors LLC now owns 10,234 shares of the company’s stock worth $590,000 after buying an additional 294 shares during the period. 14.04% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of analysts have recently commented on the company. Sanford C. Bernstein raised Sanofi to a “strong-buy” rating in a research report on Thursday, January 30th. Deutsche Bank Aktiengesellschaft upgraded Sanofi from a “sell” rating to a “hold” rating in a research note on Thursday, January 30th. Finally, StockNews.com cut Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. Two investment analysts have rated the stock with a hold rating, one has given a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $60.00.

Sanofi Trading Down 1.0 %

Shares of SNY stock opened at $53.99 on Friday. The company has a current ratio of 1.46, a quick ratio of 0.74 and a debt-to-equity ratio of 0.15. Sanofi has a 12-month low of $45.22 and a 12-month high of $58.97. The stock has a market capitalization of $137.02 billion, a P/E ratio of 21.68, a P/E/G ratio of 0.99 and a beta of 0.57. The firm’s 50 day moving average is $50.18 and its 200 day moving average is $52.42.

Sanofi (NASDAQ:SNY) last announced its earnings results on Thursday, January 30th. The company reported $0.70 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.58%. Research analysts expect that Sanofi will post 4.36 earnings per share for the current year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.